NasdaqCM - Delayed Quote • USD
ProPhase Labs, Inc. (PRPH)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 7:49 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | -- |
| Avg. Estimate | -0.41 | -0.41 | -1.55 | 0 |
| Low Estimate | -0.41 | -0.41 | -1.55 | 0 |
| High Estimate | -0.41 | -0.41 | -1.55 | 0 |
| Year Ago EPS | 0.03 | -0.2 | -0.98 | -1.55 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 4M | 4M | 22M | 131.37M |
| Low Estimate | 4M | 4M | 22M | 131.37M |
| High Estimate | 4M | 4M | 22M | 131.37M |
| Year Ago Sales | 19.3M | 14.14M | 45.24M | 22M |
| Sales Growth (year/est) | -79.30% | -71.70% | -51.40% | 497.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.09 | -0.14 | -0.19 | -0.26 |
| EPS Actual | 0.03 | -0.2 | -0.3 | -0.51 |
| Difference | 0.12 | -0.06 | -0.11 | -0.25 |
| Surprise % | 133.30% | -42.90% | -57.90% | -96.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.41 | -0.41 | -1.55 | 0 |
| 7 Days Ago | -0.41 | -0.41 | -1.55 | 0.53 |
| 30 Days Ago | -0.16 | -0.12 | -0.37 | 0.53 |
| 60 Days Ago | -0.16 | -0.12 | -0.37 | 0.53 |
| 90 Days Ago | -0.16 | -0.12 | -0.37 | 0.53 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PRPH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -1,466.70% | -- | -- | 0.80% |
| Next Qtr. | -105.00% | -- | -- | 9.60% |
| Current Year | -58.20% | -- | -- | 4.50% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | 389.90% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/21/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/10/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/14/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/2/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/12/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 3/8/2023 |
Related Tickers
BIAF bioAffinity Technologies, Inc.
2.7900
-4.12%
SERA Sera Prognostics, Inc.
9.79
+1.14%
GENE Genetic Technologies Limited
2.4400
-22.78%
OCX OncoCyte Corporation
2.5600
-1.16%
RDNT RadNet, Inc.
47.61
-0.40%
EXAS Exact Sciences Corporation
63.48
+0.41%
FLGT Fulgent Genetics, Inc.
20.11
+0.10%
FONR FONAR Corporation
16.83
+1.85%
ISPC iSpecimen Inc.
0.4210
+97.65%
MYGN Myriad Genetics, Inc.
18.51
-0.70%